89bio Newsroom

Evercore Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $33

Moomoo NewsNov 11 08:31 ET

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)

TipRanksNov 11 08:17 ET

H.C. Wainwright Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsNov 11 07:34 ET

89bio Analyst Ratings

BenzingaNov 8 12:35 ET

Raymond James Maintains Strong Buy on 89bio, Lowers Price Target to $49

BenzingaNov 8 12:35 ET

RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Maintains Target Price $12

Moomoo NewsNov 8 07:35 ET

89bio (ETNB) Gets a Hold From RBC Capital

TipRanksNov 8 07:09 ET

89bio Analyst Ratings

BenzingaSep 20 12:14 ET

Leerink Partners Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $34

Moomoo NewsAug 7 01:32 ET

Buy Rating Affirmed for 89bio: Promising Pegozafermin Trials and Regulatory Confidence

TipRanksAug 7 01:28 ET

89bio Price Target Cut to $12.00/Share From $13.00 by RBC Capital

Dow JonesAug 6 08:54 ET

Evercore Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $33

Moomoo NewsAug 6 08:34 ET

RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Cuts Target Price to $12

Moomoo NewsAug 6 07:31 ET

89bio (ETNB) Receives a Hold From RBC Capital

TipRanksAug 6 07:04 ET

89bio Analyst Ratings

BenzingaAug 6 06:44 ET

H.C. Wainwright Maintains 89bio(ETNB.US) With Buy Rating, Maintains Target Price $29

Moomoo NewsAug 6 06:31 ET

Buy Rating Affirmed for 89bio Amid Promising Pegozafermin Clinical Trials

TipRanksAug 6 06:29 ET

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

BenzingaJul 1 11:07 ET

89bio Analyst Ratings

BenzingaJul 1 11:05 ET

89bio Analyst Ratings

BenzingaJun 17 13:30 ET